perennial allergic rhinitis. other allergic rhinitis/perennial allergic rhinitis
Conditions
Interventions
Treated with 100 IU Botulinium Toxin type A admixed with 10cm nasal tampons which remained in their nasal cavities for 30 minutes. Intervention 2: Control group
Treated with the same method as intervention group ,but nasal tampons mixed with Normal Saline which remained in their intranasal cavities for 30 minutes.
Treatment - Drugs
Placebo
Intervention group
Treated with 100 IU Botulinium Toxin type A admixed with 10cm nasal tampons which remained in their nasal cavities for 30 minutes.
Control group
Sponsors
University of Social Welfare and Rehabilitation sciences
Eligibility
Sex/Gender
All
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Males and females age between 20-40; Having perennial (minimum of three years) allergic rhinitis who have received conventional treatments with no results; Having a minimum educational level ( high school diploma); Being stable in emotional,physical and other health status suitable for entering study ; Informed consent to be understood and be signed voluntarily. Exclusion criteria: Ages below 20 or above 40 years; History of chronic sinusitis,asthma and or other systemic disoredrs ; History of using Botulinium Toxin type -A for any reason; Rejecting to accept and or signing the informed consent.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relieving symptoms of perennial allergic rhinitis such as itching(eyes,ears and nose),sneez and rhinorrhea after intervention. Timepoint: 1,3,6 and 12 weeks post intervention. Method of measurement: smyptoms chart converting qualitative symptoms of itching(eyes,ears,nose),sneez and rhinorrhea to quantitative from no symptoms(0) to worst symptoms(10) .Scorings are collected in both groups for final statistical analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Observing any drug`s side effects in intervetion group. Timepoint: 1,3,6 and 12 weeks post intervention. Method of measurement: Recording any kinds of side effects in pre-designed chart related to each patient from degrees of not having (0) to sever degrees of side effects (10). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Hashem Shemshadi
University of social Welfare and Rehabilitation Sciences
Outcome results
None listed